Helium-oxygen mixture: clinical applicability in an intensive care unit
- By Medicine Mates
- Posted 165 days ago
Helium-oxygen mixture: clinical applicability in an intensive care unit
1Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
To evaluate if distress respiratory decreases after using helium-oxygen mixture in pediatric patients diagnosed with bronchospasm.
This is a retrospective, non-randomized study that included patients diagnosed with bronchospasm, who received a helium-oxygen mixture at three time points (30, 60, and 120 minutes) according to the organization protocol singular, and were admitted to the intensive care unit, from January 2012 to December 2013. This protocol includes patients with bronchospasm who sustained a modified Wood score of moderate to severe, even after one hour of conventional treatment.
Twenty children were included in the study. The mean score of severity of the disease at the initial moment was 5.6 (SD:2.0), and at moment 120 minutes, it was 3.4 (SD: 2.0). The severity score showed a significant improvement as of 30 minutes (p<0.001).
The use of helium-oxygen mixture proved to be effective in diminishing the respiratory distress score for children with airway obstructions; it should be considered a supplementary therapeutic option, together with drug therapy, in specific clinical situations.
Key words: Respiratory insufficiency; Child; Intensive care units, neonatal; Oxygen inhalation therapy; Heliotherapy
Helium gas was discovered by a French astronomer in 1868, but it was only isolated on Earth in 1895. Its molecular weight was determined in 1907.(1) Its physical and chemical characteristics consist of low molecular weight, low density (one third of the density of oxygen), high viscosity, high diffusion coefficient (greater than that of carbon monoxide), and it is a biologically inert gas.(1,2) Its use in clinical practice was based on these characteristics. Commercially, we find the mixture at concentrations 80:20 (80% helium and 20% oxygen), 70:30, and 60:40 – respectively, helium:oxygen concentrations.
The clinical applicability of Heliox® is described primarily in obstructive diseases, such as asthma, bronchiolitis, and laryngitis.(3-6) Due to the physical-chemical properties of the mixture (especially low density and high viscosity), it has a direct influence on the flow and resistance of the respiratory system.(3,7) In 1934, Barach et al., confirmed that the use of the helium-oxygen mixture (heliox) decreases the transpulmonary pressure and improves tidal volume in an experimental study with tracheostomized dogs.(8)
Physiologically, the proximal airways have a turbulent flow pattern which becomes laminar in the terminal airways. In patients with obstructive disease, the turbulent flow of the proximal airways worsens respiratory distress and decreases lung ventilation. The use of heliox changes the flow pattern in the proximal airways from turbulent to laminar, thus decreasing respiratory work.(9,10)
The report of Heliox® use in children with asthma has shown conflicting results. Conventional treatment is sufficient in most cases of disease exacerbation. Since it is a more expensive gas that oxygen, Heliox® should not be used as a first choice; whereas in more severe cases, it seems to be beneficial, and its early use can decrease respiratory work and dyspnea.(11)
There is a great difference in establishing a consensus as to the use of Heliox® in children due to the difference in criteria related to inclusion, time of intervention, treatment given, and severity of the disease in known studies. The role of Heliox® in the exacerbation of asthma has not yet been determined.(12,13)
On the other hand, some studies have identified the effect of Heliox® in the production of particles by jet nebulizers. The delivery efficacy of aerosol with Heliox® is related to its low density. By becoming laminar, the turbulent flow improves ventilation in high resistance areas, affording optimization of aerosol deposition in lower airways.(14-16)
The use of the helium-oxygen mixture is not restricted to patients with spontaneous breathing. Its benefits may be associated to use of non-invasive and even invasive ventilation - as long as the synergistic treatments are taken into consideration.(17-19)
The effect of Heliox® in decreasing the inflammatory process of respiratory distress syndrome patients, despite being confirmed, is not yet understood.(20) Even so, the clinical applicability of the helium-oxygen mixture has gained prominence in intensive therapy environments, even though there still is no consensus as to its use.
To evaluate the efficacy of the clinical response to the use of the helium-oxygen mixture in patients with severe obstructive conditions.
A retrospective observational study on the analysis of the medical records of children, conducted in a private hospital in the city of São Paulo (SP).
Children aged zero to 14 years were included, admitted to the pediatric intensive care unit, with a diagnosis of bronchospasm and/or wheezing, and who used the helium-oxygen mixture, as per the organization protocol, between January 1st , 2012 and December 31st, 2013.
The variables collected in the medical records for analysis of the clinical outcome were severity score; heart rate; respiratory rate; and oxygen saturation (SpO2) soon after the installation of the mixture, time point zero, 30 minutes, 60 minutes and 120 minutes.
Children were evaluated as to need for oxygen for maintenance of pulse oximetry (SpO2) greater than 92% and degree of respiratory distress, evaluated by the modified Wood clinical asthma score ( Table 1 ). Additional oxygen was initiated when SpO2 presented with values inferior to 92%. The oxygen flow utilized was the minimum necessary to maintain SpO2 >93%. The helium-oxygen mixture was initiated as per the organization protocol.
Table 1 Modified Wood clinical asthma score
Source: Translated and modified from: Cambonie G, Milési C, Fournier-Favre S, Counil F, Jaber S, Picaud JC, et al. Clinical effects of heliox administration for acute bronchiolitis in young infants. Chest. 2006;129(3):676-82.(4)
SatO2: oxygen saturation; RA: room air; FiO2 : inspired fraction of oxygen.
Heliox® use protocol
The organization protocol for the use of the helium-oxygen mixture included patients diagnosed with bronchospasm and/or wheezing who maintained a Wood score ≥3 ( Table 1 ) after one hour of conventional treatment, regardless of the fraction of oxygen previously used.
The use of salbutamol, predinisolone, methylpredinisolone, inhalation with hypertonic solution, antibiotics, respiratory physical therapy, and oxygen therapy were considered conventional treatment, and was maintained even after initiating the helium-oxygen mixture.
For installation of the helium-oxygen mixture, the Heliox® torpedo was used at the concentration of 70:30 (70% helium and 30% oxygen) with a specific non-rebreather mask ( Figure 1 ) and a flow of 10L/minute. Patients who did not maintain SpO2 >92% with 30% O2 had the mixture enriched with 2LO2, totalizing 40% de oxygen.
Patients who did not maintain SpO2 >92% with 40% oxygen and/or who did not present with any improvement in the severity score after one hour of Heliox®, had its use discontinued.
Sample calculation was based on the study by Cambonie et al.,(4) who assumed a mean of respiratory distress score of 5.4 and standard deviation of 0.2. Thus, it was estimated that a sample of ten individuals was sufficient to detect a minimum difference of 0.3 unit in the distress score, hence assuming a type I error at 5% and a 90% power.
Measurements were described by individual and average profile graphs, accompanied by confidence intervals. Assessment of the progression of the Wood clinical asthma score, heart rate, and respiratory rate was made by means of Student’s t test for paired samples.
The project was submitted to and approved by the Research Ethics Committee of Hospital Israelita Albert Einstein , official opinion number 687.992, CAAE: 32371514.0.0000.0071.
The study included 20 patients admitted to the intensive treatment unit of a private hospital in São Paulo, from January 2012 to December 2013, and diagnosed as bronchospasm and/or wheezing. Age range of 1 to 158 months, median of 16 months (interquartile interval – IQI: 10 to 74 months). The mean length of stay was 5.7 days (standard deviation − SD – of 3.19). Drug treatment was not changed because of the study. Bronchodilators (salbutamol) were used in 100% of cases, oral corticosteroids (prednisolone) were given on 14 (70%) occasions, and 4 (20%) patients received intravenous corticosteroids (methylprednisolone). Inhalation with a hypertonic solution was prescribed for 30% of patients and antibiotics for 80%. The treatment considered prophylactic was maintained during hospitalization for three patients, in which each one of them received a different type of medication, namely: montelukast (Singulair®), fluticasone propionate (Flixotide®), and fluticasone associated with salmeterol (Seretide®). Respiratory physical therapy was done in 100% of patients. The time between the start of conventional treatment and the introduction of Heliox® showed a median of 10 hours (3 to 53 hours).
The variables to evaluate the clinical outcome are shown on table 2 . In two cases, treatment with Heliox® was associated with noninvasive ventilation. Heliox® was discontinued due to treatment failure in three (25%) patients − two of them after 30 minutes and one after 60 minutes. Of these, one required invasive mechanical ventilation.
Table 2 Severity score, heart and respiratory rates at zero, 30, 60 and 120 minutes
HR: heart rate; RR: respiratory rate.
The mean disease severity score at time point zero was 5.6 (SD 2.0) and at time point 120 minutes, it was 3.4 (SD 2.0). This difference found in the severity score was statistically different as of 30 minutes (p<0.001), according to what is presented in figure 2 . The heart rate evaluation showed significance only at the first time point of the study, but this relevance was not sustained ( Figure 3 ). The variation of respiratory rate showed a similar progression as the severity score, also showing significance as of 30 minutes ( Figure 4 ). We did not observe a relation between the days of hospitalization and the severity score (r=0.15 and p=0.4).
95%CI: 95% confidence interval.
Figure 2 Mean profiles of Wood clinical asthma score per time (pre, 30, 60 and 120 minutes)
95%CI: 95% confidence interval.
Figure 3 Mean profiles of heart rate per time (pre, 30, 60 and 120 minutes)
Over the last decades, the number of studies aiming to confirm the efficacy of the helium-oxygen mixture use in obstructive diseases, such as asthma, bronchiolitis and airway obstruction, has increased.(4,12-15,21,22) Our study proves to be particularly important since it provides data for the Brazilian population, in which we note a scarcity of results as to clinical applicability of the helium-oxygen mixture, especially regarding the pediatric population.
In a cohort study of the Brazilian population, which included 111 infants diagnosed as acute viral bronchiolitis, the mean length of stay was 9.5 days. In this study, treatment of the illness was conventional and there was no use of the helium-oxygen mixture.(23) Whereas in the study conducted with asthmatic children, also without the use of Heliox®, the mean length of stay was 6.0 days.(24) In our study, the mean length of stay was lower, but it is not yet possible to affirm that these results are associated with the use of Heliox®. Liet et al., did not observe a relation between use of the mixture and a reduction in hospitalization time.(25)
Regarding treatment used during hospitalization, our study showed a high rate of utilization of bronchodilators and oral steroids, a treatment strongly recommended by the Global Initiatives for Asthma.(26)
Another recommendation of the Global Initiatives for Asthma(26) would be the use of the heliox only one hour after starting the conventional drug treatment. In our study, the time between the start of drug treatment and the installation of the helium-oxygen mixture was 10 hours. This datum reinforces the result that the improvement of patients was related to the introduction of the Heliox®, and not to the drug treatment effect.
Martinón-Torres et al., followed up non-intubated children with bronchiolitis and concluded that children who received Heliox® presented improved respiratory and heart rates, besides remaining less time at the intensive care unit.(27) In the children included in our study, besides the distress score, we followed up respiratory and heart rates. Use of the helium-oxygen mixture showed a significant reduction in the respiratory distress score and in respiratory rate of our patients in the first 30 minutes, with a continued reduction for up to 120 minutes.
The most significant improvement of the distress score in the first 30 minutes can be attributed to the change in airflow pattern, which becomes more laminar with the use of Heliox®. However, the progressive improvement of the children throughout time may be related to a better lung deposition of the inhaled drug (bronchodilators) with the use of Heliox®.
These data confirm the results of Kress et al., who conducted a randomized study with 45 asthmatic children, in which 22 received albuterol with Heliox®, and 23 with oxygen. They observed a statistically significant improvement in the forced expiratory volume in one second (FEV1) in the Heliox® group.(28) Braun Filho et al., compared the administration of bronchodilators in the conventional manner with the administration of inhaled medication with a mixture of helium gas and observed that the use of Heliox® decreased the risk of permanence of the patient in the observation room.(29)
In our study, three patients did not present with an improved distress score, and Heliox® was discontinued: one of them used invasive mechanical ventilation. In two successful cases, there was an association with noninvasive ventilation. With a good response, this association is indicated, since Heliox® and noninvasive mechanical ventilation are considered synergistic and complementary therapies; we further point out, however, that the need for ventilators prepared to receive the mixture limits the process. Martinón-Torres et al., conducted a randomized crossover study in 12 infants diagnosed with bronchiolitis, noting a significant improvement of SpO2 and of respiratory work, when noninvasive mechanical ventilation was associated with Heliox®.(30) A review as to the use of noninvasive mechanical ventilation with Heliox® reinforces the complementary role of both therapies, exposing that the association of the two can guarantee a promising future for the treatment of various illnesses.(19)
Recent studies have demonstrated that the use of Heliox® with a high-flow nasal cannula had a significant influence on the improvement of oxygenation and respiratory rate, and can be a successful alternative in the future, since it demands more accessible equipment than the microprocessed ventilators used in noninvasive mechanical ventilation.(31,32)
In our study, we chose to observe the cases of bronchospasm and wheezing, disorders in which Heliox® improved gas exchange, decreased respiratory work, and prevented reintubation.(33)
Our protocol included children who maintained the moderate to severe severity score after one hour of conventional treatment. This limited the number of children included in the study, since the majority of children with obstructive diseases improved with conventional intervention during the first hour. Another limitation of the study is that it was retrospective, which limits the results and its interpretations.
There still is no consensus as to the use of the helium-oxygen mixture, and the great difficulty in conclusion is in the difference of study designs, inclusion criteria, disease severity, treatment, and time when intervention started.(34)
Use of Heliox® in children with obstructive diseases showed positive outcomes, with a significant reduction in the distress score and respiratory rate in the first 30 minutes of use. Therefore, Heliox® can be considered a support in the treatment of patients with respiratory failure from obstructive causes.
1. Hess DR, Fink JB, Venkataraman ST, Kim IK, Myers TR, Tano BD. The history and physics of heliox. Respir Care. 2006;51(6):608-12. Review. [ Links ]
2. Jolliet P, Tassaux D. Helium-oxygen ventilation. Respir Care Clin N Am. 2002;8(2):295-307. Review. [ Links ]
3. Myers TR. Use of heliox in children. Respir Care. 2006;51(6):619-31. Review. [ Links ]
4. Cambonie G, Milési C, Fournier-Favre S, Counil F, Jaber S, Picaud JC, et al. Clinical effects of heliox administration for acute bronchiolitis in young infants. Chest. 2006;129(3):676-82. [ Links ]
5. Fink JB. Opportunities and risks of using heliox in your clinical practice. Respir Care. 2006;51(6):651-60. Review. [ Links ]
6. Moraa I, Sturman N, McGuire T, van Driel ML. Heliox for croup in children. Cochrane Database Syst Rev. 2013;(12):CD006822. Review. [ Links ]
7. Ho AM, Dion PW, Karmakar MK, Chung DC, Tay BA. Use of heliox in critical upper airway obstruction. Physical and physiologic considerations in choosing the optimal helium: oxygen mix. Resuscitation. 2002;52(3):297-300. [ Links ]
8. Barach AL, Eckman M. The effects of inhalation of helium mixed with oxygen on the mechanics of respiration. Ann Inter Med. 1935;9:739-65. [ Links ]
9. Papamoschou D. Theoretical validation of the respiratory benefits of helium-oxygen mixtures. Respir Physiol. 1995;99(1):183-90. [ Links ]
10. Rogers MC. Textbook of Pediatric Intensive Care. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1996. [ Links ]
11. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: a national clinical guideline [Internet]. Scottish Intercollegiate Guidelines Network, British Thoracic Society; 2008. Revised 2012 Jan [cited 2018 Jan 17]. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2012/ [ Links ]
12. Gupta VK, Cheifetz IM. Heliox administration in the pediatric intensive care unit: an evidence-based review. Pediatr Crit Care Med. 2005;6(2):204-11. Review. [ Links ]
13. Frazier MD, Cheifetz IM. The role of heliox in paediatric respiratory disease. Paediatric Respir Rev. 2010;11(1):46-53; quiz 53. Review. [ Links ]
14. Kim IK, Saville AL, Sikes KL, Corcoran TE. Heliox-driven albuterol nebulization for asthma exacerbation: an overview. Respir Care. 2006;51(6):613-8. Review. [ Links ]
15. Brandão DC, Britto MC, Pessoa MF, de Sá RB, Alcoforado L, Matos LO, et al. Heliox and forward-leaning posture improve the efficacy of nebulized bronchodilator in acute asthma: a randomized trial. Respir Care. 2011; 56(7):947-52. [ Links ]
16. Piva JP, Menna Barreto SS, Zelmanovitz F, Amantéa S, Cox P. Heliox versus oxygen for nebulized aerosol therapy in children with lower airway obstruction. Pediatr Crit Care. 2002;3(1):6-10. [ Links ]
17. Venkataraman ST. Heliox during mechanical ventilation. Respir Care. 2006; 51(6):632-9. Review. [ Links ]
18. Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care. 2007;13(1):27-38. Review. [ Links ]
19. Martinón-Torres F. Noninvasive ventilation with helium-oxygen in children. J Crit Care. 2012;27(2):220. e1-9. Review. [ Links ]
20. Yilmaz S, Daglioglu K, Yildizdas D, Bayram I, Gumurdulu D, Polat S. The effectiveness of heliox in acute respiratory distress syndrome. Ann Thorac Med. 2013;8(1):46-52. [ Links ]
21. Kass JE, Castriotta RJ. Heliox therapy in acute severe asthma. Chest. 1995;107(3):757-60. [ Links ]
22. Grosz AH, Jacobs IN, Cho C, Schears GJ. Use of helium–oxygen mixtures to relieve upper airway obstruction in a pediatric population. Laryngoscope. 2001;111(9):1512-4. [ Links ]
23. Rubin FM, Fisher GB. [Clnical and transcutaneous oxygen saturation characteristics in hospitalized infants whith acute viral bronchiolitis]. J Pediatr (Rio J). 2003;79(5):435-42. Portuguese. [ Links ]
24. Veras TN, Sakae TM. [Characteristics of children hospitalized with severe asthma in Southern Brazil]. Scientia Medica (Porto Alegre). 2010;20(3):223-7. Portuguese. [ Links ]
25. Liet JM, Ducruet T, Gupta V, Cambonie G. Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database Syst Rev. 2015;(9):CD006915. Review. [ Links ]
26. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention [Internet]. United States: GINA; 2015 [cited 2018 Apr 12] Available from: http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf [ Links ]
27. Martinón-Torres F, Rodríguez-Núñez A, Martinón-Sánchez JM. Heliox therapy in infants with acute bronchiolitis. Pediatrics. 2002;109(1):68-73. [ Links ]
28. Kress JP, Noth I, Gehlback BK, Barman N, Pohlman AS, Miller A, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbation. Am J Respir Crit Care Med. 2002;165(9):1317-21. [ Links ]
29. Braun Filho LR, Amantéa SR, Becker A, Vitola L, Marta VF, Krumenauer R. Use of helium-oxygen mixture (Heliox®) in the treatment of obstructive lower airway disease in a pediatric emergency department. J Pediatr (Rio J). 2010;86(5):424-8. [ Links ]
30. Martinón-Torres F, Rodríguez-Núñez A, Martinón-Sánchez JM. Nasal continuous positive airway pressure with heliox versus air oxygen in infants with acute bronchiolitis: a crossover study. Pediatrics. 2008;121(5):e1190-5. [ Links ]
31. Morgan SE, Vukin K, Mosakowski S, Solano P, Stanton L, Lester L, et al. Use of heliox delivered via high-flow nasal cannula to treat an infant with coronavirus-related respiratory infection and severe acute air-flow obstruction. Respir Care. 2014;59(11):e166-70. [ Links ]
32. Seliem W, Sultan AM. Heliox delivered by high flow nasal cannula improves oxygenation in infants with respiratory syncytial virus acute bronchiolitis. J Pediatr (Rio J). 2018;94(1):56-61. [ Links ]
33. Beurskens CJ, Wösten-van Asperen RM, Preckel B, Juffermans NP. The potential of heliox as a therapy for acute respiratory distress syndrome in adults and children: a descriptive review. Respiration. 2015;89(2):166-74. Review. [ Links ]
34. Gentile MA. Inhaled medical gases: more to breathe than oxygen. Respir Care. 2011;56(9):1341-57; discussion 1357-9. Review. [ Links ]
Corresponding author. Milena Siciliano Nascimento. Avenida Albert Einstein, 627/701, building A 12th floor – Morumbi Zip code: 05651-900 – São Paulo, SP, Brazil Phone: (55 11) 2151-8242 E-mail: email@example.com
Conflict of interest: none.
Print version ISSN 1679-4508On-line version ISSN 2317-6385
Einstein (São Paulo) vol.16 no.4 São Paulo 2018 Epub Nov 08, 2018
05651-901 São Paulo - SP
Tel.: (55 11) 2151 0904